Skip to main content
Premium Trial:

Request an Annual Quote

Medicare to Cover Vermillion Ovarian Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that Medicare will cover its OVA1 test for help in determining the likelihood that an ovarian mass is benign or malignant.

Highmark Medicare Services is the CMS contractor that will process Medicare claims for OVA1.

The OVA1 test was cleared for marketing in September 2009 by the US Food and Drug Administration to market its OVA1 test for helping physicians determine if a woman is at risk for a malignant pelvic mass prior to surgery. The in vitro diagnostic multivariate test utilizes five biomarkers and was developed in collaboration with Quest Diagnostics, which has exclusive rights to offer the test to the clinical lab market in the US for three years. It is the first proteomic-based IVDMIA to gain FDA clearance.

The firms launched the test earlier this week.

"This decision by Highmark Medicare Services reaffirms our belief that OVA1 can provide meaningful clinical information to assist physicians in identifying women with a high likelihood of having malignancy prior to planned surgery," Vermillion CEO Gail Page said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.